Paxman AB (PAX)

Currency in SEK
53.60
+0.20(+0.37%)
Closed·
PAX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
52.2055.00
52 wk Range
50.6085.80
Key Statistics
Prev. Close
53.4
Open
55
Day's Range
52.2-55
52 wk Range
50.6-85.8
Volume
22.87K
Average Volume (3m)
38.63K
1-Year Change
-24.93%
Book Value / Share
18.38
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PAX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

Paxman AB News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Paxman AB Company Profile

Paxman AB (publ), together with its subsidiaries, develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment worldwide. It serves various cancer centers and hospitals. The company has collaborated with the University of Huddersfield and the University of Leeds to develop a wearable medical cooling device; and the National University Hospital of Singapore for the development of a cooling and compression system. Paxman AB (publ) was founded in 1996 and is headquartered in Karlshamn, Sweden.

Employees
142
Market
Sweden

Paxman AB Earnings Call Summary for Q3/2025

  • Paxman AB reported 34% YoY revenue growth to SEK 86.9M in Q3 2025, despite stock falling 4.95% due to SEK 20M cash outflow and slower insurance-based billing adoption
  • Integration of Dignitana expanded market presence but added SEK 7.5M in costs, with total revenue comprising SEK 21M from acquisitions and SEK 1.1M from organic growth
  • Q3 financial results showed EBITDA of SEK 7.8M (9% margin), operating profit of SEK 1M, and a cash position of SEK 130M despite significant outflows
  • Company expects substantial growth in 2026, with FDA clearance for its new CIPN product anticipated in March 2026, showing impressive clinical results
  • CEO Richard Paxman expressed optimism about the company's position, focusing on transitioning to an insurance-based billing model and continued investment in reimbursement
Last Updated: 2025-11-14, 03:46 a/m
Read Full Transcript

Compare PAX to Peers and Sector

Metrics to compare
PAX
Peers
Sector
Relationship
P/E Ratio
261.8x−0.1x−0.6x
PEG Ratio
−3.150.220.00
Price/Book
2.9x1.7x2.6x
Price / LTM Sales
4.1x2.4x3.4x
Upside (Analyst Target)
87.0%−28.4%41.1%
Fair Value Upside
Unlock4.9%5.3%Unlock
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Nov 14, 2025
EPS / Forecast
0.10 / 0.20
Revenue / Forecast
86.95M / 96.75M
EPS Revisions
Last 90 days

PAX Income Statement

People Also Watch

20.68
LTMC
-1.05%
56.50
ALSTI
-0.35%
12.860
RDF
+0.63%
20,320
LPPP
-1.31%
2.590
CDGI
+2.78%

FAQ

What Is the Paxman (PAX) Stock Price Today?

The Paxman stock price today is 53.60

What Stock Exchange Does Paxman Trade On?

Paxman is listed and trades on the Stockholm Stock Exchange stock exchange.

What Is the Stock Symbol for Paxman?

The stock symbol for Paxman is "PAX."

What Is the Paxman Market Cap?

As of today, Paxman market cap is 1.25B.

What Is Paxman's Earnings Per Share (TTM)?

The Paxman EPS (TTM) is 0.23.

When Is the Next Paxman Earnings Date?

Paxman will release its next earnings report on Feb 27, 2026.

From a Technical Analysis Perspective, Is PAX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Paxman Stock Split?

Paxman has split 0 times.

How Many Employees Does Paxman Have?

Paxman has 142 employees.

What is the current trading status of Paxman (PAX)?

As of Jan 18, 2026, Paxman (PAX) is trading at a price of 53.60, with a previous close of 53.40. The stock has fluctuated within a day range of 52.20 to 55.00, while its 52-week range spans from 50.60 to 85.80.

What Is Paxman (PAX) Price Target According to Analysts?

The average 12-month price target for Paxman is SEK100.25, with a high estimate of SEK107 and a low estimate of SEK93.5. 0 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +87.03% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.